- $2.25m
- -$3.19m
- $0.07m
U.S. STOCKS ON THE MOVE-Dycom Industries, Crypto stocks, Burlington Stores
Silo Pharma rises on licensing deal for intra-nasal spray technology
Brief: Silo Pharma Enters Into Exclusive License Agreement For Intranasal Technology Used In Spc-15 Treatment For PTSD
Brief: Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
U.S. STOCKS ON THE MOVE-Moderna, Aldeyra Therapeutics, Colgate-Palmolive
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork
Brief: Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
Silo Pharma up on positive data in arthritis drug study
Brief: Silo Pharma Initiates Human Factor Study Of SPC-15 For The Treatment Of PTSD
Brief: Silo Pharma Filed Percent Patent Application Related To Methods Of Treating Alzheimer's Disease Using Prucalopride And Ketamine
Brief: Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
Brief: Silo Pharma Says On June 28, Entered Amendment To That Certain Cela Entered Into By & Between Co & University Of Maryland, Baltimore Dated Feb 26, 2021
Brief: Silo Pharma’S SPU-21 Treatment For Autoimmune Disease Awarded US Patent
U.S. STOCKS ON THE MOVE-Rio Tinto, BurgerFi International, Aclaris Therapeutics
U.S. STOCKS ON THE MOVE-Comerica, copper miners, Journey Medical
Brief: Silo Pharma Signs Agreement To Develop Ketamine Implant Therapeutic
U.S. STOCKS ON THE MOVE-Home Depot, Netflix, Bunge
Silo Pharma rises on research contract to develop implant therapeutic for pain disorder
Brief: Silo Pharma Inc - Advancing Development Of Spu-21 Liposomal Joint Homing Peptides In Collaboration With University Of Maryland, Baltimore